z-logo
Premium
Burden of serious fungal infections in Ukraine
Author(s) -
Osmanov Ali,
Denning David W.
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12409
Subject(s) - medicine , aspergillosis , pneumonia , copd , tuberculosis , allergic bronchopulmonary aspergillosis , epidemiology , asthma , mycosis , pediatrics , mucormycosis , surgery , immunology , pathology , immunoglobulin e , antibody
Summary Ukraine has high rates of TB , AIDS and cancer. We estimated the burden of fungal disease from epidemiology papers and specific populations at risk and fungal infection frequencies. HIV / AIDS cases and deaths (2012) and tuberculosis statistics were obtained from the State Service of Ukraine, while chronic obstructive pulmonary disease ( COPD ) cases were from M. Miravitlles et al., Thorax 64 , 863–868 (2009). Annual estimates are 893 579 Ukrainian women get recurrent vaginal thrush (≥4× per year), 50 847 cases of oral candidiasis and 13 727 cases of oesophageal candidiasis in HIV , and 101 (1%) of 10 085 new AIDS cases develop cryptococcal meningitis, 6152 cases of Pneumocystis pneumonia (13.5 cases per 100 000). Of the 29 265 cases of active respiratory TB in 2012, it is estimated that 2881 new cases of chronic pulmonary aspergillosis ( CPA ) occurred and that the 5‐year period prevalence is 7724 cases with a total CPA burden of 10 054 cases. Assuming adult asthma prevalence is ~2.9%, 28 447 patients with allergic bronchopulmonary aspergillosis ( ABPA ) are likely and 37 491 with severe asthma with fungal sensitisation. We estimate 2278 cases and 376 postsurgical intra‐abdominal Candida infections. Invasive aspergillosis in immunocompromised patients is estimated at 303 patients annually; 930 cases in COPD patients. Ninety cases of mucormycosis (2 per 1 000 000) are estimated. In total, ~1 000 000 (2.2%) people in Ukraine develop serious fungal infections annually.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here